Advertisement

ASCO GI 2023

Nanvuranlat Prolongs PFS in Refractory Advanced BTC

Jan 27, 2023

REFERENCES & ADDITIONAL READING

  1. Furuse J, et al. Nanvuranlat, an L-type amino acid transporter (LAT1) inhibitor for patients with pretreated advanced refractory biliary tract cancer (BTC): Primary endpoint results of a randomized, double-blind, placebo-controlled phase 2 study. Abstract 494, ASCO GI 2023, 19–21 January, San Francisco, CA, USA.

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement